Hungarian-based SOLVO and MDS Pharma Services Team Up to Offer ABC Transporter Assays
Montreal. MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, is working with Hungarian-based SOLVO Biotechnology to provide in vitro multidrug resistance (MDR) transporter assays for screening and lead optimization, as well as preclinical absorption, distribution, metabolism and excretion (ADME) studies. "Transporters are an important, evolving area in the drug metabolism arena and few contract research organizations offer this capability," said Mark Reimer, Ph.D., Senior Director, Metabolism Resource at MDS Pharma Services. "SOLVO's ATP Binding Cassette (ABC) transporter protein assays complement our existing in vitro metabolism services and are relevant to nearly all therapeutic areas."
The transport activities of ABC proteins have an important effect in general pharmacology in modulating the absorption, distribution and excretion of numerous drug compounds. The activity of these proteins in membranes comprising the blood-brain barrier and intestinal, kidney and liver epithelia, function as pharmacological barriers, inhibiting the ability of certain drug compounds to reach key organs in the body.
"An extremely important question in current pharmacological research is whether particular drugs can cross these barriers," explained Arnold Feher, M.D., M.Sc., Director of Business Development at SOLVO Biotechnology. "Since ABC-MDR transporters play a key role in these transport processes, the interaction between pharmaceuticals and ABC-MDR transporters is an essential piece of information for drug targeting. Testing the interaction between compounds and various ABC transporters may significantly help the understanding of these phenomena."
According to Dr. Reimer this is particularly helpful with cancer therapeutics, as many tumor cells over-express these transporter proteins. Treatment failure due to MDR is also found in connection with other conditions, including such therapeutic areas as central nervous system (CNS) disorders, rheumatoid arthritis and other autoimmune diseases, as well as HIV and several other infectious diseases.
Dr. Feher added that in vitro ABC-MDR transporter assays have multiple uses in screening and lead optimization for drug development, including:
* Detecting the interaction of drug candidates with a wide variety of ABC transporter proteins, including MDR1, MRPs and MXR;
* Testing the target binding of MDR modulators;
* Predicting penetration of drug candidates through pharmacological barriers;
* Predicting penetration of intracellularly active cytostatics through the membranes of tumor cells.
Other news from the department research and development
These products might interest you
Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes
Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates
Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"
Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures
Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency
Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times
Most read news
More news from our other portals
Last viewed contents
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
SEQUENOM Secures Rights to Key Non-Invasive Prenatal Diagnostic Intellectual Property
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration
